Metropolis deepens tier-II and III diagnostics network as smaller towns drive growth
Metropolis Healthcare has added 70–75 labs in smaller towns over three years and now serves about 750 towns. Tier-III and beyond contribute 27–28% of business, while June-quarter FY27 revenue rose 17% to ₹450 crore and net profit increased 26% to ₹57 crore.
What happened
Metropolis Healthcare is expanding diagnostics labs, collection centres and partnerships across smaller Indian towns as organized testing demand rises. It has
Key facts
- 27-28% of business comes from tier-III towns and beyond
- Tier-III markets growing 25-26%
- 70-75 labs added in smaller towns over the past three years
- Organized players account for 15% of India's diagnostics market
- Listed companies hold roughly 10% of the organized diagnostics segment
- India diagnostics market valued at $11 billion in 2025
- Diagnostics market projected to grow at 11% CAGR through 2034
- Four assets acquired over the past two years
- 90 labs established over the previous three years
- Network serves around 750 towns
- June-quarter FY27 revenue rose 17% YoY to ₹450 crore
- June-quarter FY27 net profit rose 26% to ₹57 crore
- Ebitda rose 27% to ₹113 crore
- Ebitda margin was 25.2%
Why this matters
Metropolis’s use of new labs, acquisitions and partnerships to penetrate smaller towns highlights a replicable inorganic-and-alliance route to build diagnostic density beyond major cities.
What to watch
- Quarterly tier-III-and-beyond revenue share, patient volumes, revenue per patient and same-center growth.
- Number of new labs, collection centers, acquisitions and partnership-led towns added versus stated expansion plans.
- EBITDA margin, employee costs, logistics costs and pre-analytical sample rejection rates as the network expands.
- Utilization levels at regional reference labs and turnaround-time performance in smaller towns.
- Share of preventive, wellness, specialized and chronic-disease testing in the revenue mix.
- Competitive pricing actions from Dr Lal PathLabs, SRL, Thyrocare, hospital chains and local diagnostic networks.
- Any regulatory changes affecting lab accreditation, sample transport, pricing or public-health testing tenders.
- Add collection centers and smaller-format labs around regional processing hubs rather than build full-service labs in every town.
- Pursue tuck-in acquisitions and partnership-led entry in states with fragmented local diagnostic providers.
- Increase direct-to-consumer preventive, wellness and chronic-care test packages to improve patient retention and test frequency.
- Expand doctor, hospital and local-clinic referral relationships to build predictable sample volumes.
- Invest in home collection, digital booking, report delivery and sample-logistics optimization to lower cost-to-serve in dispersed geographies.
- Use regional pricing and bundled offerings to defend volume while protecting premium-test mix.